MASCT-I Combined With Doxorubicin and Ifosfamide for First-line Treatment of Advanced Soft Tissue Sarcoma

Conditions: Leiomyosarcoma; Liposarcoma; Synovial Sarcoma; Angiosarcoma; Undifferentiated Pleomorphic Sarcoma; Epithelioid Sarcoma; Malignant Peripheral Nerve Sheath Tumors; Fibrosarcoma; Pleomorphic Rhabdomyosarcoma; Endometrial Stromal Sarcoma; Desmoplastic Small Round Cell Tumor Interventions: Biological: MASCT-I; Drug: Doxorubicin; Drug: Ifosfamide Sponsors: HRYZ Biotech Co. Not yet recruiting
Source: ClinicalTrials.gov - Category: Research Source Type: clinical trials